CUV — Clinuvel Pharmaceuticals Cashflow Statement
0.000.00%
- AU$551.17m
- AU$353.66m
- AU$95.50m
- 90
- 45
- 88
- 84
Annual cashflow statement for Clinuvel Pharmaceuticals, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Changes in Working Capital | 0.758 | 0.49 | 0.466 | 2.75 | 8.19 |
Other Operating Cash Flow | |||||
Cash from Operating Activities | 14.2 | 19.3 | 39.9 | 36.9 | 37.1 |
Capital Expenditures | -0.889 | -0.854 | -0.434 | -1.03 | -5.58 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | — | — | — | — | -23.5 |
Purchase of Investments | |||||
Cash from Investing Activities | -0.889 | -0.854 | -0.434 | -1.03 | -29 |
Financing Cash Flow Items | -0.018 | -0.044 | 0 | 0 | — |
Other Financing Cash Flow | |||||
Total Cash Dividends Paid | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | -1.49 | -1.48 | -1.5 | -2.24 | -3.57 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 12.5 | 15.9 | 38.8 | 35.3 | 3.31 |